Search Results | Blood | American Society of Hematology

1-20 of 49

2 3

Sort by

Sort Order Select

Journal Articles

Improved GvHD-Free, Relapse-Free Survival (GRFS) with Post-Transplant Cyclophosphamide and Tacrolimus for GvHD Prevention in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Paola Andrea Charry, Maria Queralt Salas, Alexandra Pedraza, María Suárez-Lledó, Nuria Martínez-Cibrian, Teresa Solano, Ariadna Domenech, Meritxell Nomdedeu, Joan Cid, Miquel Lozano, Laura Rosinol, Francesc Fernández-Avilés, Gonzalo Gutiérrez-García, Enric Carreras, Jordi Esteve, Álvaro Urbano-Ispizua, Montserrat Rovira, Carmen Martínez

Blood (2021) 138 (Supplement 1): 2760.

DOI: https://doi.org/10.1182/blood-2021-153366

Published: 2021

Journal Articles

Compassionate Use of Belantamab Mafodotin for Treatment of Patients with Relapsed/Refractory Multiple Myeloma Heavily Treated. Spanish Experience

Blood (2021) 138 (Supplement 1): 3775.

DOI: https://doi.org/10.1182/blood-2021-151267

Published: 2021

Journal Articles

Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial

Anna Sureda, Ana Pilar González, Javier Núñez, Javier Briones, Fátima De la Cruz, Domingo Domenech Eva, Francisca Maria Hernandez, María José Terol, Elena Amutio, Raul Cordoba, Carmen Martínez, Miriam Moreno, Antonia Rodriguez Izquierdo, Raquel Del Campo, Richard Greil, Samuel Romero, Ramón Garcia-Sanz

Blood (2021) 138 (Supplement 1): 2459.

DOI: https://doi.org/10.1182/blood-2021-150200

Published: 2021

Journal Articles

Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era

Blood (2021) 138 (Supplement 1): 3925.

DOI: https://doi.org/10.1182/blood-2021-153069

Published: 2021

Journal Articles

Acute and Post-Acute COVID-19 Severity and Mortality in Patients with Hematologic Malignancies: A Population-Based Registry Study

Blood (2021) 138 (Supplement 1): 186.

DOI: https://doi.org/10.1182/blood-2021-152539

Published: 2021

Journal Articles

Evolution of Outcome over Time for Relapsed Hodgkin Lymphoma after Autologous Stem Cell Transplant: Improved Survival for Early Relapse in Recent Years

Blood (2020) 136 (Supplement 1): 9–10.

DOI: https://doi.org/10.1182/blood-2020-138546

Published: 2020

Journal Articles

Impact of Sars-Cov-2 Infection in Hematopoietic Transplant Patients: Experience from the Madrid Group

Rebeca Bailén, MD, Mi Kwon, MD PhD, Beatriz Aguado, MD, Rafael F. Duarte, MD PhD FRCP, Maria Calbacho, MD, Anabelle Chinea, MD, Pilar Llamas, MDPhD, Rosalía Riaza Grau, Jose Angel Hernandez-Rivas, MD PhD, Victor Jimenez Yuste, MD PhD, Carmen Martínez-Chamorro, MD, F. Javier Penalver, MD, Ataulfo González, MD, Juan F del Campo, Keina Quiroz, MD, Gillen Oarbeascoa, MD, Julio Garcia Suarez, José Luis Díez-Martín, MD PhD

Blood (2020) 136 (Supplement 1): 12–13.

DOI: https://doi.org/10.1182/blood-2020-138728

Published: 2020

Journal Articles

Second Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Carmen Martinez, MD PhD, Ariane Boumendil, PhD, Joanna Romejko-Jarosinska, Achilles Anagnostopoulos, Edgar Faber, MD, Xavier Poire, MD, Ibrahim Yakoub-Agha, MD PhD, Saad Akhtar, MD, Gunhan Gurman, Vincenzo Pavone, Kazimierz Halaburda, Aida Botelho Sousa, Herv Ghesquieres, Hervé Finel, Irma Khvedelidze, Silvia Montoto, MD, Anna Sureda, MD

Blood (2018) 132 (Supplement 1): 3429.

DOI: https://doi.org/10.1182/blood-2018-99-112180

Published: 2018

Journal Articles

Post-Transplant High-Dose Cyclophosphamide Overcomes the Detrimental Effect of a Single-Locus HLA Mismatched in Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation

Patricia Ferraz, MD, Arturo Pereira, MD PhD, María Suárez-Lledó, MD, Gonzalo Gutiérrez-García, MD, Francesc Fernández-Avilés, MD, Laura Rosinol, MD PhD, Teresa Solano, Noemí Llobet, Carla Ramos, Pedro Marín, MD, Alvaro Urbano-Ispizua, MD, Montserrat Rovira, MD, Carmen Martinez, MD PhD

Blood (2018) 132 (Supplement 1): 4576.

DOI: https://doi.org/10.1182/blood-2018-99-112985

Published: 2018

Journal Articles

Nivolumab for Heavily Pretreated Relapsed/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO)

Carmen Martinez, MD PhD, Cecilia Carpio, MD, Inmaculada Heras, Eduardo Ríos Herranz, MD, Joan Buch, Antonio Gutierrez, MD PhD, Samuel Romero, Izaskun Ceberio, Irene Garcia-Garcia, Antonia Rodriguez Izquierdo, PhD, Rosalia Alonso, Joan Bargay, MD PhD, Cristina Barrenetxea Lekue, PhD, Narvaez Javier, Manuel Espeso de Haro, MD, Luis Palomera, MD PhD, Ramon García-Sanz, MD PhD

Blood (2018) 132 (Supplement 1): 2936.

DOI: https://doi.org/10.1182/blood-2018-99-115774

Published: 2018

Journal Articles

Response to Proteosome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study

Blood (2016) 128 (22): 3436.

DOI: https://doi.org/10.1182/blood.V128.22.3436.3436

Published: 2016

Journal Articles

Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Ramon Garcia-Sanz, MD PhD, Anna Sureda, MD PhD, Ana Pilar Gonzalez, MD, Fatima De la Cruz, MD PhD, Blanca Sanchez-Gonzalez, MD PhD, Antonia Rodriguez, MD PhD, Eva Domingo-Domenech, MD, Moreno Miriam, MD, Moreno Miriam, MD, Javier Lopez, Sr., MD PhD, Piñana Luis Jose, Gabriela Rodríguez, MD PhD, Miguel Canales, MD PhD, Antonio Gutierrez, MD PhD, Maria Dolores Caballero, MD PhD, Carmen Martinez, MD PhD

Blood (2016) 128 (22): 1109.

DOI: https://doi.org/10.1182/blood.V128.22.1109.1109

Published: 2016

Journal Articles

Clonal Hematopoiesis Landscape in Patients with De Novo Acute Myeloid Leukemia By Deep Sequencing

Blood (2016) 128 (22): 598.

DOI: https://doi.org/10.1182/blood.V128.22.598.598

Published: 2016

Journal Articles

Mixed Lineage Leukemia Rearrangements ( MLL- R ) Are Determinants of High Risk Disease in Homeobox A (HOXA)- deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

Blood (2015) 126 (23): 694.

DOI: https://doi.org/10.1182/blood.V126.23.694.694

Published: 2015

Journal Articles

Feasibility and Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in High-Risk AML: Real-Life Perspective from a Single Institution

Marina Diaz-Beya, MD PhD, Miguel Angel Torrente, Alfonso Ardilla, Carles Serra, Nuria Martinez, Maria Suarez-Lledo, Carmen Martinez, Francesc Fernandez, Laura Rosiñol, Gonzalo Gutierrez, Pedro Marin, Marta Pratcorona, Nuria Mariegues, Noemi Llobet, Marta Bistagne, Enric Carreras, Alvaro Urbano-Ispizua, Montserrat Rovira, Jordi Esteve, MD PhD

Blood (2015) 126 (23): 4395.

DOI: https://doi.org/10.1182/blood.V126.23.4395.4395

Published: 2015

Journal Articles

Assessment of Clinical Differences Between Starting Antimyeloma Treatment at Biological Relapse or at Clinical Relapse: Preliminary Results of an Observational Prospective Registry

Blood (2015) 126 (23): 4231.

DOI: https://doi.org/10.1182/blood.V126.23.4231.4231

Published: 2015

Journal Articles

Alternative Donors (Umbilical Cord Blood and Haploidentical Donors) for Allogeneic Stem Cell Transplantation in Relapsed / Refractory Hodgkin Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH)

Blood (2015) 126 (23): 4399.

DOI: https://doi.org/10.1182/blood.V126.23.4399.4399

Published: 2015

Journal Articles

Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Ramon Garcia-Sanz, MDPhD, Anna Sureda, MD PhD, Sara Alonso-Alvarez, MD, Ana Pilar Gonzalez, MD, Antonia Rodriguez, MD PhD, Antonio Salar, MD PhD, Fatima de la Cruz, MD, Eva Domingo, MD, Miriam Moreno, MD, Javier Lopez, Sr., MD PhD, Jose Luis Piñana, MD, Gabriela Rodriguez, Miguel Canales, Antonio Manuel Gurierrez, MD, Armando López-Guillermo, MD, María Dolores Caballero, MD PhD, Silvia Jimenez, BsC, Carmen Martinez, MD PhD

Blood (2015) 126 (23): 582.

DOI: https://doi.org/10.1182/blood.V126.23.582.582

Published: 2015

Journal Articles

Association Between Uric Acid Levels and Severe Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation

Nuria Martinez-Cibrian, Teresa Garrido, Arturo Pereira, Mauricio Sarmiento, Jose Antonio Pérez-Simón, Rocio Parody, MD, Estefania Perez, Oriana Lopez, Carlos Solano, Jose Luis Piñana, Montserrat Rovira, Francesc Fernandez-Avilés, Maria Suarez-Lledo, Alvaro Urbano-Ispizua, Carmen Martinez, MD PhD

Blood (2015) 126 (23): 5464.

DOI: https://doi.org/10.1182/blood.V126.23.5464.5464

Published: 2015

Journal Articles

Piwirna-651 Expression Influences Treatment Response and Impacts Survival in Classical Hodgkin Lymphoma Patients through Regulation of ABCC5

Alfons Navarro, PhD, Anna Cordeiro, Msc, Anna Gaya, MD, Blanca Gonzalez-Farre, MD, Marina Díaz-Beyá, MD PhD, Dolors Fuster, Carmen Martínez, MD, Jordi Esteve, MD PhD, Antonio Martinez, MD, Mariano Monzó, MD PhD

Blood (2014) 124 (21): 134.

DOI: https://doi.org/10.1182/blood.V124.21.134.134

Published: 2014

2 3

NARROW

Improved GvHD-Free, Relapse-Free Survival (GRFS) with Post-Transplant Cyclophosphamide and Tacrolimus for GvHD Prevention in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Compassionate Use of Belantamab Mafodotin for Treatment of Patients with Relapsed/Refractory Multiple Myeloma Heavily Treated. Spanish Experience

Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial

Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era

Acute and Post-Acute COVID-19 Severity and Mortality in Patients with Hematologic Malignancies: A Population-Based Registry Study

Evolution of Outcome over Time for Relapsed Hodgkin Lymphoma after Autologous Stem Cell Transplant: Improved Survival for Early Relapse in Recent Years

Impact of Sars-Cov-2 Infection in Hematopoietic Transplant Patients: Experience from the Madrid Group

Second Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Post-Transplant High-Dose Cyclophosphamide Overcomes the Detrimental Effect of a Single-Locus HLA Mismatched in Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation

Nivolumab for Heavily Pretreated Relapsed/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO)

Response to Proteosome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study

Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Clonal Hematopoiesis Landscape in Patients with De Novo Acute Myeloid Leukemia By Deep Sequencing

Mixed Lineage Leukemia Rearrangements ( MLL- R ) Are Determinants of High Risk Disease in Homeobox A (HOXA)- deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

Feasibility and Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation in High-Risk AML: Real-Life Perspective from a Single Institution

Assessment of Clinical Differences Between Starting Antimyeloma Treatment at Biological Relapse or at Clinical Relapse: Preliminary Results of an Observational Prospective Registry

Alternative Donors (Umbilical Cord Blood and Haploidentical Donors) for Allogeneic Stem Cell Transplantation in Relapsed / Refractory Hodgkin Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH)

Evaluation of the Regimen Brentuximab Vedotin Plus ESHAP (BRESHAP) in Refractory or Relapsed Hodgkin Lymphoma Patients: Preliminary Results of a Phase I-II Trial from the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Association Between Uric Acid Levels and Severe Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation

Piwirna-651 Expression Influences Treatment Response and Impacts Survival in Classical Hodgkin Lymphoma Patients through Regulation of ABCC5

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only